Barclays
RANI icon

Barclays’s Rani Therapeutics RANI Stock Holding History

Barclays’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.63K Sell
10,036
-210
-2% -$186 ﹤0.01% 4732
2026
Q1 		$7.53K Buy
10,246
+2,150
+27% +$2.75K ﹤0.01% 4735
2025
Q4 		$10.9K Buy
+8,096
New +$12.2K ﹤0.01% 4926
2024
Q2 		– Sell
-39
Closed -$121 – 5215
2024
Q1 		$121 Buy
+39
New +$134 ﹤0.01% 4993

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Barclays's RANI Position: Q2 2026 in Review

Barclays reduced its Rani Therapeutics (RANI) stake by 2% in Q2 2026, selling an estimated $186 and leaving 10,036 shares worth $7.63K. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

Barclays first reported a position in RANI in Q1 2024 and has held it in 4 quarters since. The position peaked at $10.9K in Q4 2025. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Barclays held 10,036 shares of Rani Therapeutics worth $7.63K as of Q2 2026.
  • Barclays sold 210 Rani Therapeutics shares in Q2 2026, an estimated $186.
  • Rani Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4732 holding.
  • Barclays first reported a position in Rani Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Barclays's Rani Therapeutics position peaked at $10.9K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.